A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Novartis
Merck Sharp & Dohme LLC
Ipsen
Merck Sharp & Dohme LLC
AstraZeneca
DualityBio Inc.
Constellation Pharmaceuticals
Amgen
Qilu Pharmaceutical Co., Ltd.
CellCentric Ltd.
Qilu Pharmaceutical Co., Ltd.
TYK Medicines, Inc
Arcus Biosciences, Inc.
Novartis
Evopoint Biosciences Inc.
Zenith Epigenetics
ESSA Pharmaceuticals
Astellas Pharma Inc
Corcept Therapeutics
Nuvation Bio Inc.
Zenith Epigenetics
Pfizer
Gilead Sciences